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Abstract 
Objective 
To characterize and differentiate adipose-derived stem cells (ADSCs) to 
functional smooth muscle cells (SMCs) as an alternative cell source for bladder 
engineering.  
Materials and Methods 
Rat ADSCs were differentiated into SMCs for 1 to 6 weeks using induction 
medium. The changes in contractile genes and proteins expression were 
investigated by Real time PCR, FACS, and western blot (WB) at different time 
points. In addition, spontaneous and carbachol-induced contractions of 
engineered SMC tissue at different stages were investigated to define the 
optimal duration of induction.  
Results 
We found that ADSCs differentiated into SMCs lose their capacity for expansion 
and their contractile phenotype changing to a synthetic phenotype over time. 
Highest levels of calponin, smoothelin, and MyH11 expression were observed in 
ADSCs induced for 3 weeks. Cells acquired typical SMC morphology when 
contractile proteins were expressed. However, SMC morphology was lost with 
reduction of contractile proteins, especially smoothelin and MyH11. The 
maximal spontaneous and carbachol-induced contraction of differentiated 
ADSC was after 3 weeks. 
Conclusions 
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Our study demonstrates that ADCSs are a suitable cell source for engineering 
tissues that require functional and contractile SMCs. An induction time of 3 
weeks appears to be sufficient for ADSC differentiation to contractile SMCs 
suitable for urologic tissue engineering.  
Introduction 
Over the last decades elaborate methods using gastrointestinal tissues for 
bladder reconstruction have been developed. However, there is still significant 
short and long-term complications associated with this strategy, including stone 
formation, mucus, infection and even cancer development has been reported 
[1,2]. Therefore, significant efforts have been made to engineer bladder tissues 
using autologous cells and biomaterials [3]. One of the remaining challenges is 
the availability of easy accessible healthy smooth muscle cells (SMCs) for in 
vitro expansion. 
Several groups isolated SMCs directly from biopsies of the diseased organs, 
such as bladders or vessels [4,5]. However, taking a biopsy from a targeted 
organ has several drawbacks including morbidity caused by complex surgery 
and limited sample size. Furthermore, the SMCs derived from diseased organs 
possess and maintain pathologic characteristics in vitro [6]. Mature SMCs 
isolated from healthy sources have shown limited proliferation capacity and 
usually lose their contractile phenotype followed by a change to a synthetic form 
during their in vitro expansion [4]. Therefore, alternative cell sources must be 
considered for the functional bioengineering of SM tissue. Candidate cells 
include embryonic [7] and adult stem cells [8]. The ethical issues have limited 
the use of embryonic stem cells. Adipose-derived stem cells (ADSCs) have 
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potential advantages in tissue engineering applications because of their easy 
accessibility, abundant availability and multipotency. In culture, they have 
remarkable developmental plasticity, including the ability to undergo 
multilineage differentiation and self-renewal [9]. Therefore, ADSCs seem to 
represent an excellent alternative for the bioengineering of smooth muscle. 
Other laboratories have published data on the differentiation of ADSCs into 
SMCs [10-13]. In a recent study, our group established a reliable small animal 
model for hypocontractile bladder and demonstrated that ADSCs support the 
early restoration of bladder voiding with improved voiding pressures and 
molecular expression of contractile proteins after cell therapy [14]. Although, 
ADSCs can support the regeneration of damaged bladder tissue, using pre-
differentiated contracting cells may have a better impact on the regenerated 
tissue functionality.  
Previous studies have reported the use of growth factors such as angiotensin, 
sphingosylphosphorylcholine, Transforming Growth Factor b1, and 
Transforming Growth Factor b3 [13,15] using different induction periods. To 
facilitate rapid clinical translation in near future a smooth muscle inductive 
medium (MCDB-131 medium) without growth factors was developed for SMC 
differentiation [7,8]. However, SMCs generated from ADSCs following these 
protocols were differentiated for the duration of 6 weeks in vitro and then used 
for in vivo experiments without demonstrating the maintenance of a contractile 
phenotype [8]. Compared with other cell types, little is known about the 
necessary baseline level of differentiation of ADSCs into SMCs and their 
functional characteristics. The optimal cell type for bioengineered smooth 
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muscle should exhibit the SMC phenotype and have the ability to contract. 
Differentiated SMCs can vary between two specific phenotypes: synthetic and 
proliferative or contractile and quiescent [16]. SMCs that exhibit a contractile 
phenotype are characterized by the high expression of contractile proteins 
including smooth muscle actin (SMA), calponin, caldesmon, SM22, smoothelin 
and MyH11 [17,18]. It is reasonable to assume that the optimal conditions for 
the differentiation of ADSCs into SMCs have not been well defined. Therefore, 
this study investigated the differentiation potential of ADSCs into SMCs at 
different stages of differentiation with respect to protein expression and cell 
contractility. The SMC phenotype was assessed on a molecular level by 
examining the expression of the lineage-specific markers SMA, calponin, 
smoothelin and MyH11 using different techniques. In addition, the study tested 
the functional capacity of differentiated SMCs to contract and relax 
spontaneously and upon pharmacologic stimulation in an in vitro system. 
Materials and Methods 
Isolation of adipose-derived stem cells in vitro 
To isolate ADSCs, subcutaneous adipose tissue of adult male Lewis rats (n= 
10) was excised from their inguinal regions, cut into small pieces and cells were 
isolated according to the established protocols [11,19]. All of the experiments 
were carried out using cells that were between passages 3 and 5. 
Cell characterization and multilineage plasticity 
Expanded cells were characterized by immunostaining and fluorescence-
activated cell sorting (FACS) with lineage-specific markers CD44, CD29, Stro-1, 
SSEA-1 and CD34 [20]. To further demonstrate the multipotency of the isolated 
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ADSCs a differentiation towards the adipocyte and neuron and smooth muscle 
lineages using established protocols and lineage-specific factors were 
performed [21].   
Undifferentiated ADSCs were differentiated into SMCs by incubation in SMC 
inductive MCDB 131 medium (Sigma, Buchs, Switzerland) plus 1% FBS and 
100 U/mL heparin for 1 to 6 weeks as described previously [10]. The entire 
experiment was repeated at least three times with three different samples.  
Cell proliferation 
To evaluate cells proliferation and viability during the differentiation process, 
ADSCs were cultured in SMC induction medium for 1 to 6 weeks. The cell 
proliferation reagent WST-1 (Roche, Penzberg, Germany) was used according 
to the manufacturer’s protocol. This whole experiment was repeated at least 
three times and samples were analyzed in triplicate.  
 
Real-time PCR 
Total RNA was isolated using the SV Total RNA Isolation System kit (Promega, 
Dübendorf, Switzerland) according to the manufacturer's protocol. RNA was 
reverse transcribed with random primers (High-Capacity cDNA reverse 
transcription, Life Technologies, Zug, Switzerland). Pre-designed primers for rat 
smoothelin (Rn01453105-m1), calponin (Rn00582058-m1) and MyH11 
(Rn01530326-m1) were purchased from Life Technologies (Zug, Switzerland). 
GAPDH (Rn01775763-g1) was used to normalize cDNA concentrations. All the 
values for mRNA expression were compared with the standard time point of 6 
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weeks. The entire experiment was repeated at least three times and samples 
were analyzed in triplicate.  
 
Flourescence-activated cell sorting 
Flow cytometry was performed on ADSCs and differentiated cells between 1 
and 6 weeks of differentiation. Cells were immunolabeled with hyaluronan 
receptor (CD44, Millipore, Hessen, Germany), beta-1 integrin (CD29, 
BioLegend, Fell, Germany), Stro-1 (Invitrogen, Lucerne, Switzerland) and 
hematopoietic marker (CD34, BD Biosciences, Allschwil, Switzerland) for 
ADSCs. The differentiation of ADSCs into SMCs was confirmed with the SMC 
markers anti-calponin (Sigma, Buchs, Switzerland), anti-smoothelin (Santa 
Cruz, Heidelberg, Germany), anti-MyH11 (Santa Cruz), and anti-alpha-smooth 
muscle actin (Sigma, Buchs, Switzerland).  
Immunofluorescent staining 
ADSCs were cultured on Lab-Tek chamber slides (Thermo Scientific, Nunc, 
Switzerland) in growth medium or inductive medium for the required time. The 
indirect immunostainings were performed at 4°C overnight using the following 
primary antibodies for the ADSCs: CD44, CD29, Stro-1, stage-specific 
embryonic antigen-1 (SSEA-1) and CD34.  The neurogenic differentiation was 
confirmed using mouse anti-neurofilament 68 (Sigma, Buchs, Switzerland) and 
mouse anti-beta tubulin Isotyope III (Sigma, Buchs, Switzerland) antibodies. 
The differentiation was confirmed with SMC markers as mentioned above. The 
slides were incubated with the secondary antibodies: goat anti-mouse FITC (BD 
Biosciences, Allschwil, Switzerland), goat anti-rabbit FITC (Vector lab, Servion, 
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Switzerland) or Cy3-conjugated goat anti-mouse antibody (Sigma) at room 
temperature for 1 h. The slides were counter stained with DAPI (4',6-diamidino-
2-phenylindole, Sigma). The slides were analyzed with a Leica fluorescence 
microscope (CTR 6000). Negative control consisted of secondary antibody only 
and primary antibody was omitted. For negative controls only secondary 
antibodies were added. 
Western blotting 
Cells were washed with cold PBS supplemented with a protease inhibitor 
cocktail (Sigma-Aldrich, Allschwil, Switzerland) and lysed with lysis buffer. 
Twenty-five micrograms of each sample’s protein lysate was loaded on a 12% 
gel (Bio-Rad, Cressier, Switzerland) and WB was performed according to the 
manufacturer protocol. The primary antibodies were anti-calponin, anti-
smoothelin, anti-MyH11and anti-GAPDH (Sigma, Buchs, Switzerland).  
Gel contraction assay 
To measure the spontaneous and active contractility of the differentiated 
ADSCs, small tissues with cells in collagen were formed and a contraction 
assays were performed in vitro [22] [23]. SMCs isolated from rat bladder were 
used as positive controls and undifferentiated ADSCs, a prostate cancer cell-
line (DU145) and collagen discs without cells as negative controls. The floating 
tissue-like discs was incubated in a medium containing 2% serum at 37°C for 
the indicated time periods. A digital camera at a fixed distance was used to take 
pictures. The area of the discs was calculated with ImageJ software (NIH, 
Bethesda, MD).  
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Animal ethics 
Rat fat tissue was obtained in accordance with the animal ethics guidelines. 
 
Results 
Characterization of ADSCs and multilineage differentiation 
The ADSCs proliferated quickly in culture medium, forming a uniform confluent 
monolayer and showed fibroblast-like spindle shape morphologies in phase-
contrast microscopy (Figure 1). The phenotype was confirmed by 
immunostaining with lineage-specific markers CD29, CD44, Stro-1, SSEA-1 and 
CD34 (Figure 1A, b-f). These results were confirmed by FACS analysis with the 
same markers (Figure 1C). At passage 3, ADSCs exhibited high positive 
expression of the lineage-specific markers CD29 (65% ± 5.6), CD44 (79.2% ± 
6.4), Stro-1 (54.5% ± 8) and were negative for CD34 (4.6% ± 1.1). For these 
experiments, only the ADSCs with the expression higher than 65% were used. 
Adipogenesis was confirmed 2 weeks post-induction by Oil Red O staining, 
showing intracellular lipid droplets of variable sizes, indicative of lipid 
accumulation (Figure 1B, a-b). Using neuron-specific culture conditions, the 
cells were differentiated into neurons. The differentiated cells exhibited neuron-
like morphologies, and were confirmed with the neuron-specific markers beta-III 
tubulin and neurofilament 68 (Figure 1B, 1c, 1d, 1e, 1f).  
Adipose-derived stem cell differentiation into smooth muscle  
The ADSC cells under differentiation conditions showed an increase in 
proliferation rate up to 3 weeks and a decrease after 4-6 weeks (Figure 2A). 
The induction of ADSCs in defined media elicited their differentiation into SMCs 
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as demonstrated by a gradual increase in the mRNA expression of calponin, 
MyH11, and smoothelin between 1 and 4 weeks followed by a decrease after 5 
and 6 weeks of differentiation (Figure 2B, C, D). The maximum significant 
increase of calponin, MyH11 and smoothelin was observed after 3 weeks 
compared to 6 weeks of differentiation. Similarly, the FACS data showed a 
gradual and significant increase in calponin (P=0.0002), smoothelin (P<0.0001) 
and SMA (P<0.0001) proteins after 3 weeks of differentiation compared to 
undifferentiated ADSC. The gradual increase expression of MyH11 was 
observed after 3 weeks. Comparing the expression of contractile proteins at the 
different time-points the most prominent and significant induction was observed 
over 3 weeks, followed by a significant decrease after 6 weeks (Figure 2 E, F, 
G, H). The same pattern was observed using immunofluorescent staining 
(Figure 3A). Smooth muscle induction media induced differentiation of the 
ADSCs into a SMC phenotype in which the differentiated ADSC demonstrated 
expression of SMC-specific proteins, including calponin, smoothelin and 
MyH11. Smoothelin, the key contractile protein, was reduced after 5 and 6 
weeks of differentiation. The cytoplasmic expression of MyH11 completely 
disappeared, and only slight perinuclear staining of this protein was observed. 
Cells were stained positive for SMA protein at all time-points. As shown by 
immunofluorescent, when cells were differentiated, they acquired spindle- 
shape morphology and grew in hill-and-valley pattern similar to what was 
observed in bladder tissue derived primary SMCs. This morphology was lost 
after 4-6 weeks of differentiation. The WB analysis showed increased levels of 
SMC contractile proteins, smoothelin (115 KD), calponin (34 KD) and MyH11 
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during weeks 1-4 and a reduction in their levels after 5-6 weeks of differentiation 
(Figure 3B). 
Contractility of smooth muscle cells differentiated from adipose-derived 
stem cells 
We measured the contractile ability of the cells in small bioengineered tissue 
discs. Tissues with the differentiated ADSCs displayed a maximal degree of 
spontaneous contraction after 3 weeks of differentiation. The incorporation of 
differentiated SMCs reduced the size of the tissue discs in a time-dependent 
manner up to 3 weeks, indicating good contractile tone (Figure 4A). However, 
the tissues containing ADSCs that had been differentiated for 5 and 6 weeks or 
undifferentiated ADSCs contracted to a lesser extent. Furthermore, the effect of 
contractile stimuli such as carbachol on the contraction of tissues with 
differentiated SMCs, ADSCs and primary SMCs (Figure 4B). The highest active 
contraction upon carbachol (10 µM) stimulation was observed in ADSCs 
differentiated for 3 weeks demonstrating an additional 38% contraction, which 
was comparable to tissue-isolated SMCs. Neither undifferentiated ADSCs nor 
ADSCs differentiated for more than 4 weeks showed any contraction upon 
carbachol stimulation (Figure 4C).  
 
Discussion 
Tissue engineering offers the possibility of creating functional bladder tissues 
that may replace a removed or malfunctioning bladder. Autologous cells can be 
injected directly, or a scaffold with cells can be implanted in the patient with a 
specific disease to achieve tissue regeneration [24].  The corner stone of cell-
11 
 
                             
 
based therapies is an adequate source of healthy and functional cells. The most 
important characteristic of SMCs for functional bioengineering is their contractile 
phenotype. Some groups isolated autologous SMC from biopsies [6] and 
observed a decreased contractile response in cultured neuropathic compared 
with normal SMCs. These results were consistent with in vivo studies, in which 
neuropathic and myelodysplastic bladders generated less contraction than 
normal bladders in urodynamic studies [25]. These findings imply that altered 
intracellular contractile machinery is present in diseased SMCs, which make 
them less attractive for use in tissue engineering. The ease of isolation of 
ADSCs and their multipotency make them an attractive stem cell source for use 
in bladder engineering. The focus of the present study was to evaluate the 
optimal induction time of ADSCs for differentiation into SMCs. We investigated 
the time-dependent expression of contractile proteins that generates the 
diversity of phenotypes ranging from immature cells to SMCs.  
This study demonstrated for the first time that the functionality of SMCs 
differentiated from ADSCs is time-dependent, and shorter induction times might 
be beneficial with regard to functionality and expression of contractile proteins 
and cell growth. This has potential benefits for future application since shorter 
incubation time lowers the costs and minimizes the risk of contamination. SMA 
[24] is an early SMC marker, whereas calponin, MyH11, and smoothelin are 
highly restricted to contractile, functional SMCs [16]. Smoothelin is a constituent 
of the cytoskeleton and co-localizes with actin stress fibers [26], whereas 
calponin is an actin-binding troponin-like protein that forms an integral part of 
the actin-linked contractile machinery in SMCs [27]. The importance of 
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smoothelin expression was studied in normal and overactive human bladders 
[28]. It has been shown that its expression is rapidly down-regulated in primary 
cultures of SMCs and its transcription is restricted to SMCs with contractile 
phenotypes. The up-regulation of uterine smoothelin during pregnancy has 
been reported indicating smoothelin levels directly reflect the potential of SM to 
contract [29].  
Here we demonstrated that ADSCs acquired SMCs phenotype as evidenced by 
the expression of specific genes and proteins upon induction in vitro. At mRNA 
level, ADSCs exhibited a baseline expression of SM markers, similar to other 
pluripotent stem cells. Upon induction, the highest expression of calponin and 
the late markers smoothelin and MyH11, which are only present in contractile, 
mature SMCs, was observed in cells induced for 3 weeks. With respect to 
protein expression, the differentiated cells showed an increase in calponin, 
smoothelin and MyH11 during weeks 1 to 4 and a down-regulation of MyH11 
and smoothelin after 5 and 6 weeks. It is known that smoothelin and MyH11 can 
distinguish SMCs from myofibroblasts or muscle at the synthetic stage [16]. Our 
results are consistent with a larger body of evidence showing the importance of 
contractile protein expression [30,31]. Using immunofluorescence, we 
demonstrated that the cells acquired typical SMC morphology when all of the 
contractile proteins were expressed during differentiation. However, the cells 
could only maintain their SMC phenotype during the first 3 weeks. The SMC 
morphology was lost after 4 weeks of differentiation in parallel to a reduction of 
all contractile proteins, especially smoothelin and MyH11. The expression of 
SMA protein was observed during the differentiation process with an increase 
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over time. As an early marker of SMC differentiation, SMA is often accepted to 
characterize the preliminary SMC phenotype [18] . However, expression of SMA 
can often be observed in myofibroblasts and fibroblasts.  Hence, its expression 
alone does not provide definitive evidence for the SM lineage. Here, we clearly 
demonstrated that induction times longer than 3 weeks decreases the 
expression of contractile proteins and leads to phenotypic changes. Cells 
differentiated more than 4 weeks lost their SMC morphology and increased in 
size. To confirm that the phenotypic changes and contractile proteins 
expression has an effect on functionality of the cells, small tissues were 
bioengineered ex vivo and their contractility assessed. Indeed, cells 
differentiated for more than 4 weeks showed reduced spontaneous or 
stimulated contractility.  
The use of differentiated ADSC towards functional SMCs described here not 
only serves as an easy accessible cell source for urologic tissue engineering 
but could also be used as a good non-immortalized SM cell source for in vitro 
gene expression studies, growth factors and drug testing.  
 
Conclusion 
The present study demonstrated a time-dependent gain and loss of variable 
phenotypic and functional markers of cell differentiation of murine ADSCs 
differentiated into SMCs. Our data indicates that cells after 3 weeks of 
differentiation express smooth muscle phenotype for urologic tissue engineering 
applications clearly superior to cells differentiated for 6 weeks.  
Figure 1. Characterization of rat ADSCs. 
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A-a: Phase-contrast image showing ADSCs at third passage. b-f: 
Immunofluorescent staining of ADSCs. The cells were stained with anti-CD44, 
anti-CD29, anti-CD34, and Stro-1 and SSEA-1 antibodies, respectively. The 
staining of the cells was detected using fluorescein isothiocyanate-conjugated 
(green color) secondary antibody and DAPI (blue). Scale bar = 10 μm 
 
B: Rat ADSCs cells are multipotent. a. Phase-contrast images of differentiated 
ADSC with the characteristics and morphology of adipocytes. b. Lipid clusters 
were generated in ADSCs after 2 weeks of induction in adipogenic medium as 
indicated by Oil Red O staining. 
c: Neurogenic differentiation of ADSCs. Phase-contrast images show the 
neuron-like morphology of the cells, which is indicated by arrows. d. WB 
analysis showing the expression of the 46 KD beta-III tubulin proteins. e and f. 
The cells were stained with anti-beta-III tubulin and anti-neurofilament 68 
antibodies. The staining was detected with a CY3-conjugated secondary 
antibody (red) and DAPI.  
C. Characterization of isolated ADSCs. Primary isolated ADSC’s were stained 
for CD34, CD44, Stro-1 and CD29 characterized by FACS. 
 
Figure 2. Proliferation of ADSC and time-dependent SMC-specific mRNA 
and protein expression upon differentiation.  
A. Cell proliferation rate of ADSC differentiated 1 to 6 weeks. B-D. Induction of 
the gene expression of the SM markers smoothelin, calponin and MyH11 
determined by real-time PCR with GAPDH as the control gene. *p<0.02. E-H. 
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FACS. Undifferentiated ADSCs and differentiated cells were stained with 
calponin, smoothelin, SMA and MyH11. All data represent the SEM of 3 
triplicate experiments. 
 
Figure 3. Immunostaining of ADSCs during weeks 1 to 6 of differentiation.  
Fluorescence images of ADSCs differentiated to SMCs for 1-6 weeks. The cells 
were immunostained for the SM markers SMA, calponin, and MyH11 (red-CY3), 
smoothelin (green-FITC) and nucleus staining DAPI. Scale bar = 10μm. 
B. WB analysis of SMC specific protein expression.  
 
 
Figure 4. Smooth muscle-like contractile responses of differentiated 
ADSCs.  
A. Spontaneous contraction. ADSCs were differentiated weekly, the 
differentiated SMCs and the controls embedded in collagen gel. B. Stimulated 
contraction. Collagen gels were exposed to 10 µM carbachol for 12 and 24 
hours. C. Percentage of active gel size decrease upon carbochol stimulation. 
Data represent the SEM of 3 triplicate experiments. 
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